Figure 3 Response after appearance of a new lesion

Slides:

Advertisements

Similar presentations

Reproduced with permission from Cronin M et al

Advertisements

Figure 1 Estimated annual percentages of new

Contrast-enhanced ultrasound of splenic laceration in a 20-year-old woman. CT scan of the abdomen (A) shows a well-demarcated splenic laceration (arrow).

Selinexor combines with immune checkpoint blockade to slow B16F10 melanoma tumor growth. Selinexor combines with immune checkpoint blockade to slow B16F10.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Response after initial increase in total tumour burden

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 4 Tissue infiltration and lymphadenopathy in patients with CTLA4 mutations Figure 4 | Tissue infiltration and lymphadenopathy in patients with CTLA4.

Figure 1 Concept of the therapeutic index

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 5 Schematic illustration of different clinical trial designs

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Targeted therapy in melanoma

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 3 Monitoring clonal evolution using liquid biopsies

Figure 2 Three-step approach to the assessment and management

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 5 Identification of mucinous carcinoma

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 Underreporting of treatment-related toxicities by physicians, relative to patients with either advanced-stage lung cancer, or early-stage breast.

Figure 2 Therapeutic targeting of the PI3K/AKT/mTOR pathway

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 CAR-T-cell design

Figure 4 Effects of delaying cardioprotective medications after anthracycline administration Figure 4 | Effects of delaying cardioprotective medications.

Figure 2 The association between CD8+ T‑cell density of the tumour

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Differences between MC and AC

Figure 3 Possible modalities for reconciliation of patient's and physician's report of symptomatic treatment-associated toxicities Figure 3 | Possible.

Emergence of resistance to immune checkpoint blockade is associated with elimination of mutation-associated neoantigens by LOH and a more diverse T-cell.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 NIR fluorescence is more suitable for

Ashok K. Malani, MD, MS, Brian Olofsson, MD, David Debono, MD

Figure 4 Treatment plans using stereotactic body radiotherapy (SBRT)

Otolaryngology referred this patient for imaging after palpating a mass in the “left parotid tail.” Axial contrast-enhanced CT scan through the mass reveals.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 3 Summary of overall survival by Kaplan–Meier

Figure 3 Clinical trial design in charged-particle therapy (CPT)

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Median monthly launch price of a new anticancer drug,

Axial contrast-enhanced CT scan demonstrates normal jugulodigastric lymph nodes bilaterally (curved arrows), which should not be confused with lesions.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure Immune checkpoint inhibitor–induced encephalitis before and after treatment with natalizumab Immune checkpoint inhibitor–induced encephalitis before.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Rapid Response of Brain Metastasis to Crizotinib in a Patient with ALK Rearrangement– Positive Non–Small-Cell Lung Cancer Hiroyasu Kaneda, MD, PhD, Isamu.

Example of pretreatment (A and B) and 8-week posttreatment (C and D) PET CT images. Example of pretreatment (A and B) and 8-week posttreatment (C and D)

Targeting T Cell Co-receptors for Cancer Therapy

Figure 2 Frequency and overlap of alterations

Figure 3 Tumours secrete factors that cause systemic immunosuppression

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 7 Overview of the methodological processes for

Figure 4 Radiogenomics analysis can reveal relationships

Figure 2 Radiomics in cardiology

Figure 1 Overview of the imaging biomarker roadmap

Figure 3 Determination of the primary site

Computed tomographic images from a patient with BRAFL597S-mutant metastatic melanoma responding to therapy with the MEK inhibitor TAK-733. Computed tomographic.

Mass was believed to represent a submandibular space or gland tumor by the referring general surgeon, who initially planned to excise the mass. Mass was.

Off-midline non-contrast-enhanced sagittal T1-weighted MR image (600/12/1) in a 48-year-old woman with breast cancer who presented with headache and fatigue.

A and B, Computed tomography (CT) of the chest prior to cabozantinib therapy demonstrated a dominant mass in the left upper lobe (B, black arrow), measuring.

Clinical benefit from combination limb infusion and CTLA-4 blockade.

Imaging studies in patients attaining objective response on phase I study. Imaging studies in patients attaining objective response on phase I study. A,

Antitumor activity. Antitumor activity. A, maximum change in target lesion size from baseline assessed according to RECIST 1.0 (n = 26). Six patients had.

A 63-year-old female with lung adenocarcinoma treated with nivolumab, who experienced pseudoprogression. A 63-year-old female with lung adenocarcinoma.

A, pretreatment CT scan of pelvic lymphadenopathy (identified by white arrow) in 1 patient with documented response to 1α-OH-D2. A, pretreatment CT scan.

Axial contrast-enhanced CT scan through the parotid tail demonstrates a dominant cyst (straight arrow). Axial contrast-enhanced CT scan through the parotid.

Presentation transcript:

Figure 3 Response after appearance of a new lesion in a 56-year-old woman with metastatic melanoma treated with ipilimumab3 Figure 3 | Response after appearance of a new lesion in a 56-year-old woman with metastatic melanoma treated with ipilimumab3. Contrast-enhanced CT scans of the abdomen a | before and b | 12 weeks after initiation of ipilimumab therapy revealed new subcutaneous nodule (arrow), suspected to be a new site of metastasis. c | A follow-up CT scan 24 weeks after initiation of therapy revealed resolution of the nodule, indicating response after appearance of a new lesion. Reprinted with permission from Nishino, M. et al. Personalized tumor response assessment in the era of molecular medicine: cancer-specific and therapy-specific response criteria to complement pitfalls of RECIST. AJR Am. J. Roentgenol. 198, 737–745 (2012). Nishino, M. et al. (2017) Monitoring immune-checkpoint blockade: response evaluation and biomarker development Nat. Rev. Clin. Oncol. doi:10.1038/nrclinonc.2017.88